EcoDrugPlus

Endothelin Receptor Type Aa

Ensembl ID : ENSEEEG00000010219
Gene Symbol: EDNRAA
4 Cross references
205 Possible Orthologues:

Endothelin Receptor Type Ab

Ensembl ID : ENSEEEG00000002855
Gene Symbol: EDNRAB
4 Cross references
201 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSEEEG00000018806
Gene Symbol: EDNRB
1 Cross references
200 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSEEEG00000016763
Gene Symbol: EZH2
4 Cross references
240 Possible Orthologues:

Epidermal Growth Factor Receptor A (Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog, Avian)

Ensembl ID : ENSEEEG00000004939
Gene Symbol: EGFRA
2 Cross references
212 Possible Orthologues:

Epoxide Hydrolase 2, Cytoplasmic

Ensembl ID : ENSEEEG00000009997
Gene Symbol: EPHX2
4 Cross references
204 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSEEEG00000022773
Gene Symbol: ERBB2
2 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSEEEG00000002413
Gene Symbol: ERBB3
2 Cross references
211 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3b

Ensembl ID : ENSEEEG00000023999
Gene Symbol: ERBB3B
4 Cross references
210 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSEEEG00000018064
Gene Symbol: ERBB4
2 Cross references
206 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSEEEG00000018090
Gene Symbol: ERBB4
4 Cross references
211 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSEEEG00000023134
Gene Symbol: ERBB4
1 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).